SCORE

NAN

ACER: Acer Therapeutics is a Buy


The current rating for ACER is NAN, which is -100% above its historic median rating of 50. This indicates lower risk than normal.


The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.